Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other financing activities: 2017-2022

Historic Other financing activities for UroGen Pharma (URGN) over the last 2 years, with Sep 2022 value amounting to $16,000.

  • UroGen Pharma's Other financing activities fell 86.21% to $16,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $177,000, marking a year-over-year decrease of 48.09%. This contributed to the annual value of $160,000 for FY2022, which is 11.11% up from last year.
  • UroGen Pharma's Other financing activities amounted to $16,000 in Q3 2022, which was down 70.91% from $55,000 recorded in Q2 2022.
  • In the past 5 years, UroGen Pharma's Other financing activities registered a high of $203,000 during Q1 2020, and its lowest value of $11,000 during Q4 2020.
  • Over the past 3 years, UroGen Pharma's median Other financing activities value was $36,000 (recorded in 2021), while the average stood at $64,750.
  • Data for UroGen Pharma's Other financing activities shows a peak YoY increase of 400.00% (in 2022) and a maximum YoY decrease of 86.21% (in 2022) over the last 5 years.
  • Over the past 3 years, UroGen Pharma's Other financing activities (Quarterly) stood at $11,000 in 2020, then soared by 54.55% to $17,000 in 2021, then tumbled by 86.21% to $16,000 in 2022.
  • Its Other financing activities stands at $16,000 for Q3 2022, versus $55,000 for Q2 2022 and $89,000 for Q1 2022.